Search research articles
Contact Us
Filters
Showing results (31-40 of 80) with videos related to
Page
of 8
Sort By:
American Journal of Hematology
|
August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.
British Journal of Haematology
|
December 14, 2011
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
Agostino Cortelezzi, Giuseppe Gritti, Luca Laurenti, et al.
Blood Neoplasia
|
June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 15, 2024
Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas
Lorenzo Falchi, Jahan Rahman, Lauren Melendez, et al.
Blood
|
March 12, 2014
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
Lorenzo Falchi, Michael J Keating, Edith M Marom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Candida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.
American Journal of Clinical Pathology
|
September 11, 2021
Global Cytopathology-Hematopathology Practice Trends
Sara L Zadeh, Ronald Balassanian, Matthew C Cheung, et al.
Blood Advances
|
July 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL
Isil Altintas, Christopher Morehouse, Elena Favaro, et al.
Blood
|
November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Jennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
American Journal of Hematology
|
September 29, 2011
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience
Luca Laurenti, Michela Tarnani, Ilaria Nichele, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 80) with videos related to
Sort By:
Page
of 8
American Journal of Hematology
|
August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.
British Journal of Haematology
|
December 14, 2011
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
Agostino Cortelezzi, Giuseppe Gritti, Luca Laurenti, et al.
Blood Neoplasia
|
June 24, 2025
CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
Paola Ghione, Kurt S Bantilan, Erel Joffe, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 15, 2024
Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas
Lorenzo Falchi, Jahan Rahman, Lauren Melendez, et al.
Blood
|
March 12, 2014
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
Lorenzo Falchi, Michael J Keating, Edith M Marom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Candida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.
American Journal of Clinical Pathology
|
September 11, 2021
Global Cytopathology-Hematopathology Practice Trends
Sara L Zadeh, Ronald Balassanian, Matthew C Cheung, et al.
Blood Advances
|
July 10, 2026
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL
Isil Altintas, Christopher Morehouse, Elena Favaro, et al.
Blood
|
November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Jennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
American Journal of Hematology
|
September 29, 2011
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience
Luca Laurenti, Michela Tarnani, Ilaria Nichele, et al.
Page
of 8